Mink selected for five presentations at society for immunotherapy of cancer's (sitc) 37th annual meeting

New york, oct. 05, 2022 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced the acceptance of five abstracts for presentation at the society for immunotherapy of cancer's (sitc) 37th annual meeting, to be held november 8 – 12th, 2022.
INKT Ratings Summary
INKT Quant Ranking